STOCK TITAN

Aequus Pharmaceuticals Inc - AQSZF STOCK NEWS

Welcome to our dedicated news page for Aequus Pharmaceuticals (Ticker: AQSZF), a resource for investors and traders seeking the latest updates and insights on Aequus Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aequus Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aequus Pharmaceuticals's position in the market.

Rhea-AI Summary
Aequus Pharmaceuticals reports financial results for Q2 2023. Revenue decreased by 71% compared to last year. Net losses decreased by 9.22% in Q2 2023. Sales of Evolve branded eyedrops paused in Canada. General administration costs decreased by 23% in Q2 2023. Sales and marketing costs decreased by 44% in Q2 2023. R&D expenses increased in Q2 2023. G&A expenses decreased by 36% in YTD 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.91%
Tags
-
Rhea-AI Summary
Aequus Pharmaceuticals launches preservative-free Bimatoprost for glaucoma patients in Canada
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Rhea-AI Summary
Aequus Pharmaceuticals launches user-friendly education website for patients and professionals, featuring preservative-free multi-dose Bimatoprost. Positive response from Canadian physicians at COS conference. Website aims to empower users with comprehensive resources and expert guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Aequus Pharmaceuticals pauses sales of Evolve Intensive eyedrop and gel products in Canada due to MDSAP certification process. Sales will resume once certification is issued.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Aequus Pharmaceuticals reports financial results for Fiscal 2022, with an operating loss of $2.7 million. The company is focusing on launching its prescription product, ZIMED®, in the next 3 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.75%
Tags
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
46.27%
Tags
none
Aequus Pharmaceuticals Inc

OTC:AQSZF

AQSZF Rankings

AQSZF Stock Data

1.44M
112.79M
14.68%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Canada
Vancouver